Evidence map›Paper›PMID 37068915›Full record

ArticleRMD open2023

Characteristics and outcomes of SARS-CoV-2 breakthrough infections among double-vaccinated and triple-vaccinated patients with inflammatory rheumatic diseases.

Rebecca Hasseli, Jutta G Richter, Bimba Franziska Hoyer, Hanns-Martin Lorenz, Alexander Pfeil, Anne Constanze Regierer, Tim Schmeiser, Anja Strangfeld, Reinhard E Voll, Andreas Krause and 17 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in RMD open, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. [The German COVID-19 rheumatism register].Zeitschrift fur Rheumatologie · 2024
    Article
  4. Article
  5. Observational
  6. Observational
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Rebecca HasseliDepartment of Internal Medicine D, Section of Rheumatology and Clinical Immunology, University Hospital Munster, Munster, Germany hasseli@rheumathek.de.ORCID 0000-0002-2982-8253
Jutta G RichterClinic for Rheumatology, University Hospital Duesseldorf, Medical Faculty of Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany.
Bimba Franziska HoyerClinic for Internal Medicine I, Rheumatology and Clinical Immunology, University Medical Center Schleswig-Holstein Campus, Kiel, Germany.ORCID 0000-0002-5252-1719
Hanns-Martin LorenzDivision of Rheumatology, Department of Medicine V, University Hospital Heidelberg, Heidelberg, Germany.
Alexander PfeilDepartment of Internal Medicine III, University Hospital Jena, Jena, Germany.ORCID 0000-0002-2709-6685
Anne Constanze RegiererEpidemiology Unit, German Rheumatism Research Centre, Berlin, Germany.ORCID 0000-0003-2456-4049
Tim SchmeiserRheumatology, Private Practice "Rheumatologie im Veedel" Cologne, Cologne, Germany.ORCID 0000-0001-7342-0020
Anja StrangfeldEpidemiology Unit, German Rheumatism Research Centre, Berlin, Germany.ORCID 0000-0002-6233-022X
Reinhard E VollDepartment of Rheumatology and Clinical Immunology, Medical Center - University of Freiburg, Faculty of Medicine, Freiburg, Germany.
Andreas KrauseDepartment of Rheumatology, Clinical Immunology and Osteology, Immanuel Hospital, Berlin, Germany.
Sabine ReckertRheumatology, Private Practice, Potsdam, Germany.
Anett GräßlerRheumatology, Private Practice, Pirna, Germany.
Petra SaarRheumatology, Private Practice Endokrinologikum, Frankfurt, Germany.
Andreas KapelleRheumatology, Private Practice, Hoyerswerda, Germany.
Marina BackhausDepartment of Internal Medicine, Rheumatology and Clinical Immunology, Park-Klinik Weissensee, Academic Hospital of the Charité Berlin, Berlin, Germany.
Norbert BlankDivision of Rheumatology, Department of Medicine V, University Hospital Heidelberg, Heidelberg, Germany.
Joerg HenesCentre for Interdisciplinary Clinical Immunology, Rheumatology and Autoinflammatory Diseases (INDIRA) and Department of Internal Medicine II (Oncology, Haematology, Rheumatology and Clinical Immunology), University Hospital Tuebingen, Tuebingen, Germany.
Silke OsiekRheumatology, Private Practice Dialysezentrum, Schweinfurt, Germany.
Anna KnotheDepartment of Rheumatology and Clinical Immunology, Campus Kerckhoff, Justus Liebig University Giessen, Giessen, Germany.
Guido HoeseRheumatology, Private Practice, Stadthagen, Germany.
Jan Brandt-JürgensRheumatology, Private Practice, Berlin, Germany.
Anja MaltzahnRheumatology, Private Practice, Göttingen, Germany.
Christof SpeckerDepartment of Rheumatology and Clinical Immunology, KEM Kliniken Essen-Mitte, Essen, Germany.ORCID 0000-0003-2504-3229
Ulf Müller-LadnerDepartment of Rheumatology and Clinical Immunology, Campus Kerckhoff, Justus Liebig University Giessen, Giessen, Germany.
Hendrik Schulze-KoopsDivision of Rheumatology and Clinical Immunology, Department of Internal Medicine IV, Ludwig-Maximilians-University, Munich, Germany.ORCID 0000-0002-1681-491X
COVID-19 task force of the German Society of Rheumatology collaborators
COVID19-Rheuma.de collaborators

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo analyse the clinical profile of SARS-CoV-2 breakthrough infections in at least double-vaccinated patients with inflammatory rheumatic diseases (IRDs).

methodsData from the physician-reported German COVID-19-IRD registry collected between February 2021 and July 2022 were analysed. SARS-CoV-2 cases were stratified according to patients' vaccination status as being not vaccinated, double-vaccinated or triple-vaccinated prior to SARS-CoV-2 infection and descriptively compared. Independent associations between demographic and disease features and outcome of breakthrough infections were estimated by multivariable logistic regression.

resultsIn total, 2314 cases were included in the analysis (unvaccinated n=923, double-vaccinated n=551, triple-vaccinated n=803, quadruple-vaccinated n=37). SARS-CoV-2 infections occurred after a median of 151 (range 14-347) days in patients being double-vaccinated, and after 88 (range 14-270) days in those with a third vaccination. Hospitalisation was required in 15% of unvaccinated, 8% of double-vaccinated and 3% of triple-vaccinated/quadruple-vaccinated patients (p<0.001). Mortality was 2% in unvaccinated, 1.8% in the double-vaccinated and 0.6% in triple-vaccinated patients. Compared with unvaccinated patients, double-vaccinated (OR 0.43, 95% CI 0.29 to 0.62) and triple-vaccinated (OR 0.13, 95% CI 0.08 to 0.21) patients showed a significant lower risk of COVID-19-related hospitalisation. Using multivariable analysis, the third vaccination was significantly associated with a lower risk for COVID-19-related death (OR 0.26; 95% CI 0.01 to 0.73).

conclusionsOur cross-sectional data of COVID-19 infections in patients with IRD showed a significant reduction of hospitalisation due to infection in double-vaccinated or triple-vaccinated patients compared with those without vaccination and even a significant reduction of COVID-19-related deaths in triple-vaccinated patients. These data strongly support the beneficial effect of COVID-19 vaccination in patients with IRD. TRIAL REGISTRATION NUMBER: EuDRACT 2020-001958-21.

Indexed as

COVID-19Rheumatic DiseasesBreakthrough InfectionsCOVID-19 VaccinesCross-Sectional StudiesHumansSARS-CoV-2COVID-19 Vaccinesantirheumatic agentsCOVID-19inflammationvaccination

Identifiers

PMID37068915
PMCPMC10111193

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.